title: K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Miller
authors.forename: Nicolas
authors.initials: N
authors.lastname: Margot
authors.forename: Damian
authors.initials: D
authors.lastname: McColl
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Cheng
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019380:Anti-HIV Agents / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000494:pharmacology*; D000068698:Tenofovir; D017211:Treatment Failure
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine